Urology Research Laboratory

As the major academic center in the Kansas City area, we feel very strongly about clinical research. It is only through such research have miraculous breakthroughs occurred in the field of medicine. However, our primary concern is always patient safety, which is why all clinical trials at the University of Kansas Hospital are subjected to multiple scrutinizing reviews. This ensures the privacy and safety of all our patients participating in clinical studies.

Our physicians are constantly evaluating new therapies for our urological patients. As the only Urologic Academic Center in the area performing clinical trials we are often the only hope for the patients who have failed conventional therapies. We work closely with physicians in all other fields including medical oncologists, radiation oncologists, radiologists, cardiologists, and internal medicine doctors to provide comprehensive care for our patients with difficult to treat urologic problems.

Dr. Thrasher and Dr. Holzbeierlein are also actively involved in a number of investigational clinical protocols that are examining new treatments for patients with prostate, kidney, and bladder cancer. As a member of the Southwest Oncology Group, an organization dedicated to the advancement of the treatment of Urologic Cancer, the physicians at KUMC are on the cutting edge of the latest urologic cancer treatments.

Marilyn Labinski, our clinical study research coordinator, is actively involved in the oncology clinical trails for the Department of Urology at the University of Kansas Medical Center. She actively participates in helping patients who wish to participate in our Urology clinical research.

Clinical Trials:

• Griebling TL (PI): Prospective, Multicenter, Randomized, Parallel-Group Trial, Comparing the Safety and Efficacy of InterStim® Therapy to Standard Medical Therapy for Subjects with Symptoms of Overactive Bladder (Medtronic InSite UI protocol #1634 and Medtronic InSite UF protocol #1635). Sponsor: Medtronic, Inc. 2007-present. Study open to enrollment.
  
  
• Griebling TL (PI): A 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Sponsor: Pfizer, Inc. 2009-present. Study open to enrollment.
  
  
• Griebling TL (PI): A 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Sponsor: Pfizer, Inc. 2009-present. Study open to enrollment.

Click here for print ready PDF version of Urology Protocol List

Contact Us today to learn more.